Breast Cancer

Orion Genomics announces collaboration to validate clinical utility of breast cancer screening test

Published in Genetics and Environmental Business Week, November 16th, 2006

Orion Genomics has initiated collaboration with Mayo Clinic to study the clinical utility of Orion's breast cancer screening tests, which are based on epigenetic biomarkers that were discovered using Orion's cutting-edge DNA methylation technologies.

Under the collaboration, physicians and scientists at Mayo Clinic and Orion will validate the tumor specificity of Orion's breast cancer biomarkers by analyzing the cross reactivity of these epigenetic biomarkers in more than a dozen additional cancer types.

"We are pleased to collaborate with Mayo Clinic, one of the most prestigious reference laboratories and medical institutions in the world," said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week

Source: Genetics and Environmental Business Week (2006-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry